Rofleponide
![]() | |
| Clinical data | |
|---|---|
| Other names | 6α,9α-Difluoro-11β,16α,17α,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic (R)-16,17-acetal with butyraldehyde; 16α,17α-[(1R)-butylidenebis(oxy)]-6α,9α-difluoro-11β,21-dihydroxypregn-4-ene-3,20-dione |
| Drug class | Corticosteroid; Glucocorticoid |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H34F2O6 |
| Molar mass | 468.538 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rofleponide is a synthetic glucocorticoid corticosteroid which was never marketed.[1][2][3][4]
References
- ^ "Rofleponide". AdisInsight.
- ^ Ahlström-Emanuelsson C, Andersson M, Persson C, Schrewelius C, Greiff L (2004). "Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis". Clin. Exp. Allergy. 34 (5): 731–5. doi:10.1111/j.1365-2222.2004.1965.x. PMID 15144464. S2CID 1480600.
- ^ K Nagaraju (30 November 2013). Manual of Pediatric Allergy. JP Medical Ltd. pp. 109–. ISBN 978-93-5090-498-5.
- ^ Jonathan A. Bernstein (27 May 2016). Rhinitis, An Issue of Immunology and Allergy Clinics of North America, E-Book. Elsevier Health Sciences. pp. 407–. ISBN 978-0-323-44468-2.
